Please login to the form below

Not currently logged in
Email:
Password:

Takeda forms new women's health and cancer company

Recruits former Medivation CMO Lynn Seely to lead Myovant Sciences

TakedaTakeda has siphoned its women's health and prostate cancer operations into a new biopharma firm, created in conjunction with pharmaceutical holding company Roivant Sciences.

Myovant Sciences will focus on delivering innovative therapies in the two areas, with former Medivation chief medical officer Lynn Seely appointed to lead the business.

Vivek Ramaswamy, chief executive at Roivant Sciences, said that the creation of Myovant is a “win-win” for patients as it looks to “address major unmet medical needs in women's health, prostate cancer and beyond”.

A 30-year old former hedge fund partner, Ramaswamy is best known for last year launching the biggest ever US biotech IPO and has told Forbes he wants his firm to be the “Berkshire Hathaway of drug development”.

Roivant describes its work as helping biopharma companies “unlock value from their pipelines by completing the clinical development of promising drug candidates”, that might otherwise not have been invested in.

For its tie-up with Takeda, the Japanese firm has granted Myovant Sciences an exclusive, worldwide license for its prostate cancer candidate relugolix, with the exception of Asian markets.

The once-daily, oral drug is currently in phase III trials and has demonstrated 'significant clinical benefit', according to the company.

Myovant has also received an exclusive, commercial license for RVT-602, Takeda's oligopeptide kisspeptin receptor agonist for the treatment of female infertility.

Andrew Plump, chief medical and scientific officer at Takeda, said that Myovant will succeed in bringing relugolix to market by uniting the new company's “in-house development capabilities” and “deep expertise” with its parent company's “commercial presence in certain Asian territories”.

The move comes as Takeda looks to focus its resources on oncology, gastroenterology and central nervous system diseases, with Plump adding that the firm is “establishing a strategy that embraces innovative partnerships” in these three areas.

Article by
Rebecca Clifford

7th June 2016

From: PME

Share

Tags

COVID-19 Updates and Daily News

Featured jobs

PMHub

Add my company
Accession

Accession was a born from a passion and a vision. A passion to harness the power of market access to...

Latest intelligence

Why big pharma needs to be braver
The last few years have seen the pharmaceutical industry undergo a rapid metamorphosis in the face of unprecedented change, but communications are one area that still needs an injection of...
Leveraging Real-World Evidence for Cell and Gene Therapies
Regulators and reimbursement bodies are increasingly turning to real-world evidence (RWE) to understand the long-term value of drugs, in particular novel therapies. Here, Mariam Bibi, Senior Director, Global RWE at...
Food Allergy – Is avoidance the only option?
Following on from Allergy Awareness Week 2022, we’re continuing the discussion about food allergies and the experiences of those who live with them. In this blog, we discuss the current...